Articles for this Review were found through searches of PubMed and Embase by use of the terms ācardiovascular toxicityā, ācardiotoxicityā, ācancer treatmentā, āchemotherapyā, ābiochemicalā, āendothelial damageā, āgenetic variationsā, āelectrocardiographyā, āechocardiographyā, āMultiple Gated Acquisition Scanā, āMagnetic Resonance Imagingā, āPositron Emission Tomographyā, and āSingle Photon Emission Tomographyā. Trials with highest quality study design were selected. Only studies of
ReviewCardiovascular toxicity caused by cancer treatment: strategies for early detection
Introduction
Methods for detection and treatment of different types of cancer have developed impressively in the past 20 years. Life-expectancy for patients with cancer is steadily improving, with an age-adjusted 10-year survival of 70% for breast cancer, 80% for Hodgkin's disease, and 90% for testicular cancer.1 Around 3 million patients are diagnosed with cancer in Europe each year, which means there is a large group at risk of treatment-related complications.2 Long-term complications include development of second malignancies and cardiovascular disease, but up to now, the incidence and extent of these complications in adults are largely unknown. By contrast, studies of childhood cancer survivors have produced many more data on long-term complications of treatment.3
In trials of adjuvant anthracycline-based treatment for breast cancer, 5-year incidence of chronic heart failure is between 0% and 3Ā·2%, depending on the combination regimen and cumulative dose of anthracycline.4 However, long-term follow up of cardiovascular morbidity and mortality is not available. A large meta-analysis of the Early Breast Cancer Trialists' Collaborative Group, in which 42ā000 patients with breast cancer participated in 78 randomised trials, found that patients treated with radiotherapy had a high rate of non-breast cancer mortality, mainly from heart-disease (rate ratio 1Ā·12). This high rate of heart disease was observed during the first 5 years after treatment and continued for up to 15 years.5 However, data are partly based on outdated radiation-techniques in use from 1976 until 1995.
10 years ago, we reviewed methods for detection of anthracycline-induced cardiotoxicity.6 Improvements have since resulted in more sensitive monitoring strategies (Figure 1, Figure 2). Changes in cancer treatment have introduced both, more as well as less, potentially cardiotoxic regimens, through the increased use of anthracyclines, platinum compounds, radiation therapy, and introduction of monoclonal antibodies such as trastuzumab and bevacizumab.
Although monitoring guidelines exist for several potentially cardiotoxic treatments, little data are available to formulate evidence-based screening and follow-up recommendations for treatment-induced cardiotoxicity. In 2007, the American Society of Clinical Oncology (ASCO) Survivorship Expert Panel clearly stated the need for such recommendations.7
In this Review, we give an update of the methods available for early detection of cardiac damage caused by cancer treatment. Each method is assigned a level of evidence backing up its applicability, according to the system used by the Oxford Centre of Evidence Based Medicine (panel 1).8 Level 1a evidence is viewed as definite and level 5 as weak. Most studies reviewed in this paper were not designed to assess the sensitivity of monitoring strategies as a primary goal, which implies that level of evidence is based on indirect evidence or retrospective data.
Section snippets
Detection of treatment-induced cardiotoxicity
Cardiac function is monitored during a potentially cardiotoxic cancer treatment to identify patients who are susceptible to this toxicity as early as possible and prevent morbidity and mortality. Efforts to prevent further complications include intensified monitoring, initiation of preventive measures, or changes to cancer treatments. Detection of possible toxicity should not result in holding back an essential treatment, which would compromise effectiveness.
Mitani and colleagues9 did a
LVEF
Measurement of LVEF with multiple gated acquisition (MUGA) scintigraphy and echocardiography,12 gives an assessment of systolic cardiac function and is the most common method of monitoring cardiac function during cancer treatment. However, LVEF can underestimate actual cardiac damage13 because of the compensatory reserve of the myocardium that enables adequate ventricular output even in the presence of dysfunctional myocytes. With left ventricular dysfunction, deterioration of diastolic cardiac
Methods for assessment of cardiovascular function
Strategies for early detection of potential cardiovascular damage from cancer treatment will be addressed. Advantages, disadvantages, and level of evidence behind each strategy are summarised in panel 2.
Conclusion
The identification of patients who are at an increased risk of cardiovascular damage caused by cancer treatment can be achieved by detection of early changes in cardiovascular function and estimation of a baseline risk of late morbidity (figure 3).16, 17, 18, 19 Current guidelines and monitoring strategies for detection of cardiovascular toxicity caused by cancer treatment are mostly derived from medium-level evidenceātrue even for MUGA scintigraphy (panel 2).
LVEF is the most widely used
Search strategy and selection criteria
References (73)
- et al.
Recent cancer survival in Europe: a 2000ā02 period analysis of EUROCARE-4 data
Lancet Oncol
(2007) - et al.
Estimates of the cancer incidence and mortality in Europe in 2006
Ann Oncol
(2007) - et al.
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
Lancet Oncol
(2005) - et al.
Detection of anthracycline-induced cardiotoxicity
Cancer Treat Rev
(1999) - et al.
Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
J Nucl Cardiol
(2003) - et al.
Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later
J Am Coll Cardiol
(2008) - et al.
Cardiotoxicity of cytotoxic drugs
Cancer Treat Rev
(2004) - et al.
Cardiac complications of radiation therapy
Clin Oncol (R Coll Radiol)
(2005) - et al.
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
Ann Oncol
(2002) - et al.
Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function
J Am Coll Cardiol
(1997)
Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics
Am Heart J
Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines
Ultrasound Med Biol
QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide
Lancet
Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function
J Am Coll Cardiol
Elevated B-type natriuretic peptide levels after anthracycline administration
Am Heart J
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
Cancer Treat Rev
Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells
Exp Toxicol Pathol
Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappaB/Rel
Toxicol Appl Pharmacol
Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer
Eur J Cancer
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Ann Oncol
Assessment of cardiac sympathetic neuronal function using PET imaging
J Nucl Cardiol
Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy
Eur J Cancer
(111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
Eur J Cancer
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
J Cardiovasc Magn Reson
Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990ā2004
J Natl Cancer Inst
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Lancet
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects
J Clin Oncol
Oxford Centre for Evidence-based Medicine Levels of Evidence
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society
Circulation
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Late Effects Committee and Nursing Discipline
J Clin Oncol
Monitoring of anthracycline-induced cardiotoxicity
Ann Pharmacother
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
J Clin Oncol
Detection and monitoring of cardiotoxicity-what does modern cardiology offer?
Support Care Cancer
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
J Clin Oncol
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin
Cancer Res
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
Cancer
Cited by (226)
Nuclear medicine imaging methods of radiation-induced cardiotoxicity
2022, Seminars in Nuclear MedicineCitation Excerpt :For accurate follow-up of the LVEF in cancer patients treated with cardiotoxic agents, it is important to obtain a baseline LVEF before the start of treatment.83 During follow-up, serial measurements of the LVEF are performed to create a risk assessment of cardiotoxicity and to assess cardiac function before, during and after anticancer treatment.83-85 LVEF can be measured by multigated acquisition (MUGA), quantitative gated blood-pool Single-Photon Emission Computed Tomography (SPECT), two- and three-dimensional echocardiography and cardiovascular magnetic resonance imaging (CMR).
Myocardial Deformation Imaging by Speckle-Tracking Echocardiography for Assessment of Cardiotoxicity in Children during and after Chemotherapy: A Systematic Review and Meta-Analysis
2022, Journal of the American Society of EchocardiographyHiPSCs for population genetics
2022, Current Topics in iPSCs TechnologyCancer treatment-related cardiovascular disease: Current status and future research priorities
2021, Biochemical PharmacologyImpact of malignancy on clinical outcomes in patients with acute coronary syndromes
2021, International Journal of CardiologyCardioOncology
2021, Sex Differences in Cardiac Diseases: Pathophysiology, Presentation, Diagnosis and Management